Nicergoline: Indication, Dosage, Side Effect, Precaution

This information is not country-specific. Please refer to the Myanmar prescribing information.

Generic Medicine Info

Indications and Dosage

Oral
Cerebrovascular insufficiency, Dementia, Peripheral circulatory disorders

Adult: 30 mg 1-2 times daily. Dosage recommendations may vary among countries or individual products. Refer to specific product guidelines.

Administration

Should be taken on an empty stomach.

Special Precautions

Patient with hyperuricaemia or history of gout. Renal impairment. Pregnancy.

Adverse Reactions

Significant: Hypotension, hyperuricaemia.
Gastrointestinal disorders: Gastric distress, pyrosis, constipation, diarrhoea, vomiting.
General disorders and administration site conditions: Tiredness.
Nervous system disorders: Dizziness, cephalea.
Psychiatric disorders: Insomnia, drowsiness.
Reproductive system and breast disorders: Sexual impotence, decreased libido.
Vascular disorders: Flushing.

Drug Interactions

May potentiate the effect of antihypertensive drugs.

Action

Description: Nicergoline is a semisynthetic ergot derivative that produces arteriolar vasodilatation both by direct vascular mechanism and by changes in tissue metabolism. At the cerebral level, it increases arterial flow and consumption of oxygen and glucose, thus reducing vascular resistance. It also exerts serotonergic and dopaminergic effects, antiplatelet activity, and improves EEG patterns.
Pharmacokinetics:
Absorption: Rapidly and well-absorbed. Bioavailability: 5%. Time to peak plasma concentration: 1.5-3 hours (nicergoline); 3-5 hours (MDL); 0.5-1 hour (MMDL).
Distribution: Volume of distribution: 224 L. Plasma protein binding: 34.7% (MDL); 14.7% (MMDL).
Metabolism: Metabolised mainly via hydrolysis to 1-methyl-10 alpha-methoxy-9,10-dihydrolysergol (MMDL), then demethylated by CYP2D6 to form the main active metabolite 10-alpha-methoxy-9, 10-dihydrolysergol (MDL).
Excretion: Mainly via urine (82%); faeces (10%). Elimination half-life: 11-20 hours (MDL).

Chemical Structure

Storage

Store below 30°C. Protect from moisture.

MIMS Class

Peripheral Vasodilators & Cerebral Activators

ATC Classification

C04AE02 - nicergoline ; Belongs to the class of ergot alkaloids. Used as peripheral vasodilators.

References

Anon. Nicergoline. Lexicomp Online. Hudson, Ohio. Wolters Kluwer Clinical Drug Information, Inc. https://online.lexi.com. Accessed 09/11/2021.

Buckingham R (ed). Nicergoline. Martindale: The Complete Drug Reference [online]. London. Pharmaceutical Press. https://www.medicinescomplete.com. Accessed 09/11/2021.

Sermion (Pfizer). MIMS Thailand. http://www.mims.com/thailand. Accessed 09/11/2021.

Disclaimer: This information is independently developed by MIMS based on Nicergoline from various references and is provided for your reference only. Therapeutic uses, prescribing information and product availability may vary between countries. Please refer to MIMS Product Monographs for specific and locally approved prescribing information. Although great effort has been made to ensure content accuracy, MIMS shall not be held responsible or liable for any claims or damages arising from the use or misuse of the information contained herein, its contents or omissions, or otherwise. Copyright © 2024 MIMS. All rights reserved. Powered by MIMS.com